Aptevo Therapeutics (NASDAQ:APVO) Trading Up 3% – What’s Next?

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s stock price shot up 3% during trading on Thursday . The company traded as high as $4.86 and last traded at $4.86. 15,800 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 34,356 shares. The stock had previously closed at $4.72.

Analyst Ratings Changes

A number of research firms have commented on APVO. Weiss Ratings downgraded shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, May 26th. Wall Street Zen raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Aptevo Therapeutics Stock Performance

The firm has a market cap of $5.98 million, a P/E ratio of -0.02 and a beta of 1.68. The business’s 50-day simple moving average is $4.84 and its 200 day simple moving average is $8.66.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($6.41). As a group, equities research analysts expect that Aptevo Therapeutics Inc. will post -24.13 EPS for the current year.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.